Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: An evidence-based approach

Women's Health

Volumn 8, Issue 2, 2012, Pages 191-203

  Kumar Dhingra, Vandana ^a   Kand, Purushottam ^b   Basu, Sandip ^b  

^a HIMALAYAN INSTITUTE HOSPITAL TRUST   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

computed tomography; fluorodeoxyglucose; ovarian cancer; ovarian carcinoma; PET; PET computed tomography

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; EVIDENCE BASED MEDICINE; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; OVARY CARCINOMA; OVARY METASTASIS; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

DECISION MAKING; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECURRENCE;

EID: 84858054639     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.91     Document Type: Review

References (68)

1. Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst. Rev. 3, CD004706 (2009).
2. Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No 5, version 2.0. IARC Press, Lyon, France (2004).
3. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. IARC Scientific Publication, Lyon, France, 8, 155 (2002).
4. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: Survival of cancer patients diagnosed 1990-1994 - results and commentary. Ann. Oncol. 14(SUPPL5), v61-v118 (2003). (Pubitemid 46417464)
5. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
6. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynaecol. 96(8), 889-892 (1989).
7. Basu S, Kwee TC, Surti S, Akin EA, Yoo D, Alavi A. Fundamentals of PET and PET/CT imaging. Ann. NY Acad. Sci. 1228, 1-18 (2011).
8. Liu Y. Benign ovarian and endometrial uptake on FDG PET-CT: Patterns and pitfalls. Ann. Nucl. Med. 23(2), 107-112 (2009).
9. Nishizawa S, Inubushi M, Ozawa F, Kido A, Okada H. Physiological FDG uptake in the ovaries after hysterectomy. Ann. Nucl. Med. 21(6), 345-348 (2007). (Pubitemid 47283255)
10. Zhu ZH, Cheng WY, Cheng X, Dang YH. Characteristics of physiological uptake of uterus and ovaries on 18F-fluorodeoxyglucose positron emission tomography. Zhong Guo Yi Xue Ke Xue Yuan Xue Bao 29(1), 124-129 (2007). (Pubitemid 46420999)
11. Kim SK, Kang KW, Roh JW, Sim JS, Lee ES, Park SY. Incidental ovarian 18F-FDG accumulation on PET: Correlation with the menstrual cycle. Eur. J. Nucl. Med. Mol. Imaging 32(7), 757-763 (2005).
12. Nam EJ, Yun MJ, Oh YT et al. Diagnosis and staging of primary ovarian cancer: Correlation between PET/CT, Doppler US, and CT or MRI. Gynecol. Oncol. 116(3), 389-394 (2010).
13. Yoshida Y, Kurokawa T, Kawahara K et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am. J. Roentgenol. 182(1), 227-233 (2004). (Pubitemid 38017747)
14. Schröder W, Zimny M, Rudlowski C, Büll U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int. J. Gynecol. Cancer 9(2), 117-122 (1999). (Pubitemid 29220748)
15. Kawahara K, Yoshida Y, Kurokawa T et al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J. Comput. Assist. Tomogr. 28(4), 505-516 (2004). (Pubitemid 38988818)
16. Fenchel S, Grab D, Nuessle K et al. Asymptomatic adnexal masses: Correlation of FDG PET and histopathologic findings. Radiology 223(3), 780-788 (2002). (Pubitemid 34547598)
17. Rieber A, Nüssle K, Stöhr I et al. Preoperative diagnosis of ovarian tumors with MR imaging: Comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am. J. Roentgenol. 177(1), 123-129 (2001). (Pubitemid 32578064)
18. Grab D, Flock F, Stöhr I et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol. Oncol. 77(3), 454-459 (2000). (Pubitemid 30368567)
19. Kubik-Huch RA, Dörffler W, von Schulthess GK et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur. Radiol. 10(5), 761-767 (2000). (Pubitemid 30321087)
20. Fenchel S, Kotzerke J, Stöhr I et al. [Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F18 fluorodeoxyglucose]. Nuklearmedizin 38(4), 101-107 (1999). (Pubitemid 29287727)
21. Nam EJ, Yun MJ, Oh YT et al. Diagnosis and staging of primary ovarian cancer: Correlation between PET/CT, Doppler US, and CT or MRI. Gynecol. Oncol. 116(3), 389-394 (2009).
22. Kitajima K, Murakami K, Yamasaki E et al. Diagnostic accuracy of integrated FDG-PET/ contrast-enhanced CT in staging ovarian cancer: Comparison with enhanced CT. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1912-1920 (2008).
23. Yamamoto Y, Oguri H, Yamada R, Maeda N, Kohsaki S, Fukaya T. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int. J. Gynaecol. Obstet. 102(2), 124-127 (2008).
24. Castellucci P, Perrone AM, Picchio M et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl. Med. Commun. 28(8), 589-595 (2007). (Pubitemid 47067045)
25. Risum S, Høgdall C, Loft A et al. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol. Oncol. 105(1), 145-149 (2007). (Pubitemid 46454333)
26. Markman M. PET/CT scans in ovarian cancer: Prognostic versus predictive utility? Minerva Med. 100(5), 415-420 (2009).
27. Risum S, Høgdall C, Loft A et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography - a prospective study. Gynecol. Oncol. 108(2), 265-270 (2008). (Pubitemid 351181445)
28. Kurosaki H, Oriuchi N, Okazaki A et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann. Nucl. Med. 20(3), 171-174 (2006). (Pubitemid 43925959)
29. Sironi S, Messa C, Mangili G et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: Correlation with histologic findings. Radiology 233(2), 433-440 (2004). (Pubitemid 39423802)
30. Leitha T, Cesnik R, Steiner E, Frühwald F. Use of FDG-PET in the differential diagnosis of a single bone lesion in ovarian cancer. Clin. Nucl. Med. 29(3), 204-205 (2004). (Pubitemid 38298302)
31. Kim S, Chung JK, Kang SB et al. [18F] FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur. J. Nucl. Med. Mol. Imaging 31(2), 196-201 (2004). (Pubitemid 38173694)
32. Smith GT, Hubner KF, McDonald T, Thie JA. Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET. Clin. Positron Imaging 1(4), 263 (1998).
33. Risum S, Høgdall C, Markova E et al. Influence of 2-(18F) fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int. J. Gynecol. Cancer 19(4), 600-604 (2009).
34. Markman M. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol. Oncol. 114(3), 536; author reply 536-537 (2009).
35. Cuenca Cuenca JI, Borrego Dorado I, Vázquez Albertino R, Gómez Camarero P, Sanz Viedma S, Fernández López R. [Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer]. Rev. Esp. Med. Nucl. 27(6), 411-417 (2008).
36. Fagotti A, Fanfani F, Rossitto C et al. A treatment selection protocol for recurrent ovarian cancer patients: The role of FDG-PET/CT and staging laparoscopy. Oncology. 75(3-4), 152-158 (2008).
37. Lenhard MS, Burges A, Johnson TR et al. PET-CT in recurrent ovarian cancer: Impact on treatment planning. Anticancer Res. 28(4C), 2303-2308 (2008).
38. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA-125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis. Eur. J. Radiol. 71(1), 164-174 (2009).
39. Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: Comparison with integrated PET/CT. J. Comput. Assist. Tomogr. 31(6), 868-875 (2007). (Pubitemid 350196929)
40. Sheng XG, Zhang XL, Fu Z et al. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi 42(7), 460-463 (2007).
41. Sebastian S, Lee SI, Horowitz NS et al. PET-CT vs CT alone in ovarian cancer recurrence. Abdom. Imaging 33(1), 112-118 (2008).
42. García-Velloso MJ, Jurado M, Ceamanos C et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34(9), 1396-1405 (2007). (Pubitemid 47312579)
43. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol. Oncol. 105(1), 17-22 (2007). (Pubitemid 46441448)
44. Mangili G, Picchio M, Sironi S et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging 34(5), 658-666 (2007). (Pubitemid 46669366)
45. Chung HH, Kang WJ, Kim JW et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: Correlation with clinical or histological findings. Eur. J. Nucl. Med. Mol. Imaging 34(4), 480-486 (2007). (Pubitemid 46426988)
46. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol. 103(1), 271-276 (2006). (Pubitemid 44374699)
47. Hauth EA, Antoch G, Stattaus J et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur. J. Radiol. 56(2), 263-268 (2005). (Pubitemid 41483027)
48. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol. Oncol. 99(2), 294-300 (2005). (Pubitemid 41502833)
49. Nanni C, Rubello D, Farsad M et al. 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: A prospective study on forty-one patients. Eur. J. Surg. Oncol. 31(7), 792-797 (2005). (Pubitemid 41194659)
50. Bristow RE, del Carmen MG, Pannu HK et al. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol. Oncol. 90(3), 519-528 (2003).
51. Mansueto M, Grimaldi A, Mangili G et al. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: A cost-effectiveness analysis. Eur. J. Cancer Care (England) 18(6), 612-619 (2009).
52. Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol. Obstet. Invest. 55(3), 130-134 (2003). (Pubitemid 36928630)
53. Funicelli L, Travaini LL, Landoni F, Trifirò G, Bonello L, Bellomi M. Peritoneal carcinomatosis from ovarian cancer: The role of CT and [18F]FDG-PET/CT. Abdom. Imaging 35(6), 701-707 (2009).
54. Pfannenberg C, Königsrainer I, Aschoff P et al. 18F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 16(5), 1295-1303 (2009).
55. De Gaetano AM, Calcagni ML, Rufini V, Valenza V, Giordano A, Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: Diagnostic patterns, case examples and pitfalls. Abdom. Imaging 34(3), 391-402 (2009).
56. Yang QM, Bando E, Kawamura T et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 33(12), 1817-1821 (2006).
57. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: Role of 18F-FDG PET. J. Nucl. Med. 44(9), 1407-1412 (2003). (Pubitemid 39663352)
58. Nishiyama Y, Yamamoto Y, Kanenishi K et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur. J. Nucl. Med. Mol. Imaging 35(2), 287-295 (2008).
59. Avril N, Sassen S, Schmalfeldt B et al. Prediction of response to neoadjuvant chemotherapy by sequential F18 -fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J. Clin. Oncol. 23(30), 7445-7453 (2005). (Pubitemid 46291806)
60. Markman M. Use of positron emission tomography scans in ovarian cancer: A diagnostic technique in search of an indication. J. Clin. Oncol. 23(30) 7385-7387 (2005). (Pubitemid 46291795)
61. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q. J. Nucl. Med. 45(3), 257-268 (2001). (Pubitemid 34182907)
62. Iyer RB, Balachandran A, Devine CE. PET/CT and cross sectional imaging of gynaecologic malignancy. Cancer Imaging 7, Spec. no A, S130-S138 (2007). (Pubitemid 350120087)
63. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: A retrospective review. Gynecol. Oncol. 85(1), 53-58 (2002). (Pubitemid 34304010)
64. Soussan M, Wartski M, Cherel P et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol. Oncol. 108(1), 160-165 (2008). (Pubitemid 350299439)
65. Iagaru AH, Mittra ES, McDougall IR, Quon A, Gambhir SS. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl. Med. Commun. 29(12), 1046-1051 (2008).
66. Jung DC, Choi HJ, Ju W, Kim SC, Choi KG. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int. J. Gynecol. Cancer 18(4), 637-641 (2008). (Pubitemid 352020190)
67. Basu S, Baghel NS. Intense FDG uptake in the spleen due to recent granulocyte- macrophage colony-stimulating factor administration: follow-up scan clarifying the situation. J. Cancer Res. Ther. 7(2), 228-229 (2011).
68. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J. Nucl. Med. 50(Suppl1), 64S-73S (2009).